Oral Type 2 Diabetes Competitive Landscape depicts the current state of the market for oral type 2 diabetes treatments and how existing drugs shape the environment for pipeline diabetes medications. This strategy guide provides commercial teams insights on how endocrinologists and primary care providers evaluate an individual oral type 2 diabetes treatment, including its clinical benefits, as well as each drug’s target patient characteristics. Finally, the report includes data on HCP’s familiarity and expectations for pipeline oral type diabetes treatments currently in development.
As biopharma companies launch more oral therapies, the market for type 2 diabetes drugs will certainly change. The brands that HCPs rely upon most may gain or lose favor depending on changes in the overall competitive landscape.
The strategies that competing products implement may alter how endocrinologists and primary care providers think about their oral type 2 diabetes treatment options. The insights contained in this strategy guide help commercial executives develop more robust strategies for their oral type 2 diabetes treatments.
Lastly, To navigate the many challenging aspects of the current oral type 2 diabetes market, brand teams need to fully grasp how new market entrants will impact existing brands. Oral Type 2 Diabetes Competitive Landscape illustrates how new pipeline drugs will compete against existing oral type 2 diabetes brands, which products will face the biggest competition and which developing drugs have the best chance to find success.
Overview Oral Type 2 Diabetes Competitive Landscape
The oral type 2 diabetes market has multiple treatment options that endocrinologists and primary care providers evaluate when prescribing medications to their patients. Oral Type 2 Diabetes Competitive Landscape studies current type 2 diabetes market dynamics and analyzes HCPs’ expectations of the oral type 2 diabetes market’s key brands, along with important oral type 2 diabetes treatments moving through the development pipeline.
This report focuses on the oral type 2 diabetes market and its
- Current market positions
- Branded drugs
- Competitors and expectations
- Pipeline products
- Patient share per product
- Expected usage in the next year
- Prescription patterns
The data in this strategy guide cover the following oral type 2 diabetes treatements:
- Jardiance/Synjardy/Glyxambi
- Farxiga
- Januvia/Janumet
- Invokana
- Rybelsus
- Tradjenta/Jentadueto
- Onglyza/Kombiglyze
- Steglatro/Segluromet/Steglujan
The report also includes analysis of the following oral type 2 diabetes pipeline drugs:
- Oral insulin
- Sotagliflozin
Strategic Questions Answered about Oral Type 2 Diabetes Treatments and the Competitive Landscape
- Market Positions: Which oral type 2 diabetes drugs are Rising Leaders, Established Leaders, Falling Leaders, Rising Challengers, Stable Laggards and Outsiders?
- Competitive Landscape: How are oral type 2 diabetes brands competitively positioned? Who are the top 2 – 3 competitors for each of the top brands within the oral type 2 diabetes treatment landscape?
- Prescription Trends: Which brands do physicians expect to prescribe more vs. less over the next 12-months?
- Pipeline Impact: Which oral type 2 medications will be most impacted in the future by treatments currently in development?
Summary of Strategic Insights around Oral Type 2 Diabetes Competitive Landscape
- The majority of HCPs expect to Rybelsus to increase in prescriptions over the next year. While the brand does not rank highly in current patient share it is the branded drug with the largest expected increase.
- There are few brands that either Endos or PCPs expect will have changes in patent share though the next year. Seven out of eleven brands are expected to remain stable by the majority of HCPs.
- Oral insulin is expected to be most competitive with two generic options, Sulfonylureas and TZDs. This could show that HCPs believe that Oral Insulin could become a generic option for the oral type 2 diabetes category.
Benefits of Purchasing Oral Type 2 Diabetes Treatment Competitive Landscape
- Cost-efficient insights about companies and brands in the oral type 2 diabetes market to support your strategic marketing decisions.
- Insights drawn from in-depth interviews among US KOLs and surveys of more than 155 endocrinologists and primary care providers
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s type 2 diabetes strategist for 1-year.
Table of Contents
Executive Summary – 5
Research Methodology: Robust Insights from US Endocrinologists and PCPs – 6
The Strategic Six: Key Insights about the Oral T2D Competitive Landscape – 7
Oral T2D Treatment Usage Summary – 8
Oral T2D Market Summary – 9
Competitors: Current Products – 10
Oral T2D Competitive Landscape – 11
- Patient Share per Product – 12
- Increased Usage Expected in the Next Year-Total – 13
- Increased Usage Expected in the Next Year-PCPs – 14
- Increased Usage Expected in the Next Year – ENDOs – 15
- Decreased Usage Expected in the Next Year-Total – 16
- Decreased Usage Expected in the Next Year-PCPs – 17
- Decreased Usage Expected in the Next Year – ENDOs – 18
- Stable Rx Patterns – 19
Type 2 Diabetes Competitor Brand Profiles – 20
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Top Brand Competitors – 21
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Top Competitors – 22
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Brand Competitor Prescribing Patterns – 23
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Brand Competitor Rational Perceptions – 24
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Competitor Emotional Brand Personalities – 25
- Jardiance/Synjardy/Glyxambi Top Brand Competitors Brand Competitor Prescribing Patterns – 26
Farxiga Top Brand Competitors – 27
- Farxiga Top Competitors – 28
- Farxiga Brand Competitor Prescribing Patterns – 29
- Farxiga Brand Competitor Rational Perceptions – 30
- Farxiga Competitor Emotional Brand Personalities – 31
- Farxiga Brand Competitor Prescribing Patterns – 32
Januvia/Janumet Top Brand Competitors – 33
- Januvia/Janumet Top Competitors – 34
- Januvia/Janumet Brand Competitor Prescribing Patterns – 35
- Januvia/Janumet Brand Competitor Rational Perceptions – 36
- Januvia/Janumet Competitor Emotional Brand Personalities – 37
- Januvia/Janumet Brand Competitor Prescribing Patterns – 38
Invokana Top Brand Competitors – 39
- Invokana Top Competitors – 40
- Invokana Brand Competitor Prescribing Patterns – 41
- Invokana Brand Competitor Rational Perceptions – 42
- Invokana Competitor Emotional Brand Personalities – 43
- Invokana Brand Competitor Prescribing Patterns – 44
Rybelsus Top Brand Competitors – 45
- Rybelsus Top Competitors – 46
- Rybelsus Brand Competitor Prescribing Patterns – 47
- Rybelsus Brand Competitor Rational Perceptions – 48
- Rybelsus Competitor Emotional Brand Personalities – 49
- Rybelsus Brand Competitor Prescribing Patterns – 50
Tradjenta/Jentadueto Top Brand Competitors – 51
- Tradjenta/Jentadueto Top Competitors – 52
- Tradjenta/Jentadueto Brand Competitor Prescribing Patterns – 53
- Tradjenta/Jentadueto Brand Competitor Rational Perceptions – 54
- Tradjenta/Jentadueto Competitor Emotional Brand Personalities – 55
- Tradjenta/Jentadueto Brand Competitor Prescribing Patterns – 56
Steglatro/Segluromet/Steglujan Top Brand Competitors – 57
- Steglatro/Segluromet/Steglujan Top Competitors – 58
- Steglatro/Segluromet/Steglujan Brand Competitor Prescribing Patterns – 59
- Steglatro/Segluromet/Steglujan Brand Competitor Rational Perceptions – 60
- Steglatro/Segluromet/Steglujan Competitor Emotional Brand Personalities – 61
- Steglatro/Segluromet/Steglujan Brand Competitor Prescribing Patterns – 62
Onglyza/Kombiglyze Top Brand Competitors – 63
- Onglyza/Kombiglyze Top Competitors – 64
- Onglyza/Kombiglyze Brand Competitor Prescribing Patterns – 65
- Onglyza/Kombiglyze Brand Competitor Rational Perceptions – 66
- Onglyza/Kombiglyze Competitor Emotional Brand Personalities – 67
- Onglyza/Kombiglyze Brand Competitor Prescribing Patterns – 68
Pipeline Competitors – 69
Pipeline Product Familiarity – 70
- Oral Insulin (ORMD-0801) Top Brand Competitors and Expectations – 71
- Oral Insulin (ORMD-0801) Top Competitors – 72
- Oral Insulin (ORMD-0801) Expectations – 73
- Sotagliflozin Top Brand Competitors and Expectations– 74
- Sotagliflozin Top Competitors – 75
- Sotagliflozin Expectations – 76
Contact – 77
